Shares of Insulet Corp. (NASDAQ:PODD) have earned a consensus recommendation of “Buy” from the seventeen analysts that are presently covering the stock. Eight analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $41.62.
A number of brokerages have weighed in on PODD. B. Riley began coverage on Insulet Corp. in a research report on Monday, September 26th. They set a “neutral” rating and a $46.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $44.00 target price on shares of Insulet Corp. in a research report on Wednesday, June 22nd. Zacks Investment Research raised Insulet Corp. from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Tuesday, August 9th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $52.00 target price on shares of Insulet Corp. in a research report on Tuesday, August 16th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $50.00 target price (up previously from $40.00) on shares of Insulet Corp. in a research report on Thursday, August 4th.
A number of large investors have recently added to or reduced their stakes in PODD. Mitra Capital LLC purchased a new position in shares of Insulet Corp. during the first quarter worth approximately $1,781,000. Banbury Partners LLC boosted its position in shares of Insulet Corp. by 140.4% in the first quarter. Banbury Partners LLC now owns 444,668 shares of the company’s stock worth $14,745,000 after buying an additional 259,700 shares during the last quarter. Arrowgrass Capital Partners US LP purchased a new position in shares of Insulet Corp. during the first quarter worth approximately $5,565,000. Bellevue Group AG purchased a new position in shares of Insulet Corp. during the first quarter worth approximately $497,000. Finally, Integre Asset Management LLC boosted its position in shares of Insulet Corp. by 14.8% in the first quarter. Integre Asset Management LLC now owns 21,096 shares of the company’s stock worth $700,000 after buying an additional 2,727 shares during the last quarter.
Shares of Insulet Corp. (NASDAQ:PODD) opened at 38.89 on Monday. The company’s 50-day moving average price is $41.97 and its 200-day moving average price is $35.48. The firm’s market capitalization is $2.23 billion. Insulet Corp. has a 12-month low of $23.94 and a 12-month high of $45.60.
Insulet Corp. (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The firm had revenue of $87.30 million for the quarter, compared to the consensus estimate of $81.10 million. Insulet Corp. had a negative return on equity of 137.88% and a negative net margin of 17.68%. The business’s revenue was up 44.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.30) earnings per share. Analysts anticipate that Insulet Corp. will post ($0.44) EPS for the current year.
Insulet Corp. Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corp. and related companies with MarketBeat.com's FREE daily email newsletter.